NCT00170937CompletedPhase 4
A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan and Hydrochlorothiazide Combined and Alone, in Patients With Metabolic Syndrome
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Novartis
- Enrollment
- 507
- Locations
- 2
- Primary Endpoint
- Change from baseline in insulin sensitivity after 16 weeks
Study Overview
Brief Summary
The metabolic syndrome is a classification for patients with a constellation of risk factors which may include abdominal obesity, hypertension, elevated blood lipids and sugar. Three or more of these factors together constitute the metabolic syndrome and place these patients at a greater risk for the development of diabetes and cardiovascular diseases. The purpose of this study is to determine whether two common drugs to lower blood pressure, whether used separately or in combination, have different effects on blood sugar levels in patients diagnosed with the metabolic syndrome.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Double
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Waist circumference: males > 40", females > 35 "
- •MSSBP ≥ 130 mmHg but ≤ 160 mmHg and a MSDBP ≥ 85 mmHg but ≤ 100 mmHg
- •At least one of the following criteria: - Fasting plasma glucose between 5.9 and 6.9 mmol/L; - Serum triglycerides > 150 mg/dL; - LDL Cholesterol: - < 40 mg/dL males; - < 50 mg/dL females
Exclusion Criteria
- •MSSBP> 180 mmHg or MSDBP > 110 mmHg
- •Inability to discontinue all prior antihypertensives for a period of 4 weeks.
- •History of diabetes
- •History of stroke, transient ischemic attack or myocardial infarction.
- •Significant weight change > 10 lbs during screening period
- •Patients taking a diuretic for 3 months prior to screening.
- •Other protocol-defined exclusion criteria may apply.
Outcomes
Primary Outcomes
Change from baseline in insulin sensitivity after 16 weeks
Secondary Outcomes
- Change from baseline in lipid profile after 16 weeks
- Change from baseline in markers of inflammation and thrombosis after 16 weeks
- Change from baseline in a measurement of beta cell function after 16 weeks
- Change from baseline in fasting plasma glucose and fasting insulin after 16 weeks
- Adverse events, serious adverse events, laboratory values, physical examinations, and vital signs for up to 16 weeks
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Withdrawn
Not Applicable
Insulin Resistance and Insulin SecretionDiabetes Mellitus, Type 2NCT00073294National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Unknown
Not Applicable
Effects of Moderate Altitude Training on Metabolic Parameters in Voluntary Study Participants With Metabolic SyndromeMetabolic SyndromeNCT02013947Pure Mountain Solda40
Completed
Not Applicable
Peds Metabolic Syndrome in PsoriasisPsoriasisMetabolic SyndromeNCT00930592Tufts Medical Center42
Completed
Phase 2
Acetylcarnitine and Insulin SensitivityType 2 Diabetes MellitusNCT00393770Mario Negri Institute for Pharmacological Research43
Completed
Not Applicable
Study: Diet and Exercise Study to Improve Brain Blood Flow: Blood Flow Improvement TrialPreDiabetesNCT03117829University of Wisconsin, Madison30